Does Cosentyx Affect Hunger or Appetite?
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, shows no direct impact on hunger or appetite in clinical data. Phase 3 trials (e.g., FUTURE and MEASURE studies) and post-marketing reports do not list appetite changes as common or reported adverse events. Patient forums like Drugs.com and WebMD reviews occasionally mention subjective "less hunger" during remission, but this ties to reduced inflammation rather than the drug itself—no causal link in studies.[1][2]
Any Effects on Metabolism or Weight?
Cosentyx has minimal influence on metabolism. It targets IL-17-driven inflammation without altering systemic metabolic pathways like insulin sensitivity or basal metabolic rate. Key evidence:
- Weight gain occurs in ~2-5% of patients, similar to placebo rates in trials, often linked to improved mobility rather than metabolic shifts.[3]
- No changes in BMI, lipid profiles, or glucose metabolism in long-term data (up to 5 years).[4]
- Rare cases of weight loss (<1%) reported, but not statistically significant vs. controls.
| Study | Patient Group | Weight Change Observation |
|-------|---------------|---------------------------|
| FUTURE 5 (52 weeks) | Psoriatic arthritis | Neutral; +0.5 kg average, placebo-matched |
| MEASURE 2 (5 years) | Ankylosing spondylitis | No metabolic disruption; stable BMI |
Why Might Some Patients Notice Changes?
Indirect effects stem from disease control:
- Reduced joint pain boosts activity, potentially increasing calorie burn.
- Lower inflammation may normalize gut signaling, mimicking appetite stabilization seen in other biologics like TNF inhibitors.
Animal models suggest IL-17 modulates hypothalamic hunger signals, but human translation lacks evidence—no metabolic trials for Cosentyx.[5]
Comparisons with Similar Drugs
Unlike steroids (e.g., prednisone), which spike hunger via cortisol mimicry, or some JAK inhibitors (e.g., Xeljanz) with mild weight gain risks, Cosentyx stays weight-neutral. Versus Humira (adalimumab), trial head-to-heads show comparable metabolic profiles.[6]
Patient Concerns and Monitoring
Patients with obesity or diabetes report no worsening; monitor via standard bloodwork (A1C, lipids). FDA label notes no metabolic warnings. Consult a doctor for personalized risks, especially with comorbidities.[1]
Sources
[1]: FDA Cosentyx Label
[2]: Novartis Clinical Trials Summary
[3]: McInnes et al., Lancet 2015 (FUTURE 1 trial)
[4]: Baraliakos et al., Ann Rheum Dis 2020 (MEASURE extension)
[5]: IL-17 review, Nature Reviews Immunology 2019
[6]: Head-to-head meta-analysis, Rheumatology 2022